Adverse Events Induced by Nivolumab Plus Ipilimumab vs. Nivolumab Monotherapy among Cancer Patients: A Systematic Review and Meta-Analysis

被引：2
|
作者：
Kamat, Shweta [1 ]
Patel, Jay [1 ]
Brown, Britny R. [1 ]
Vyas, Ami [1 ]
机构：
[1] Univ Rhode Isl, Coll Pharm, Dept Pharm Practice, 7 Greenhouse Rd, Kingston, RI 02881 USA
来源：
CANCER INVESTIGATION | 2022年 / 40卷 / 09期
基金：
美国国家卫生研究院;
关键词：
Nivolumab; ipilimumab; immune checkpoint inhibitors; adverse events; meta-analysis; STAGE IV MELANOMA; PREDICTIVE BIOMARKERS; ADJUVANT NIVOLUMAB; DOUBLE-BLIND; IMMUNOTHERAPY;
D O I：
10.1080/07357907.2022.2108827
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A systematic review and meta-analysis of randomized controlled trials (RCTs) were performed to examine treatment-related adverse events (TRAEs) for combination of nivolumab (NIVO) and ipilimumab (IPI) compared to NIVO monotherapy among cancer patients. We searched several databases to identify relevant RCTs. Meta-analysis was performed using random-effects model. In fourteen RCTs included in the study, we found that compared to NIVO monotherapy, combination NIVO + IPI increased the risk of any grade (Risk Ratio (RR) = 1.11), and grade 3 or 4 (RR = 1.95) TRAEs. Compared to NIVO, NIVO + IPI had higher risk for any grade colitis (RR = 4.52), pneumonitis (RR = 3.06), and diarrhea (RR = 1.68).
引用
收藏
页码：777 / 788
页数：12
相关论文
共 50 条
  • [31] Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis
    Galling, Britta
    Roldan, Alexandra
    Hagi, Katsuhiko
    Rietschel, Liz
    Walyzada, Frozan
    Zheng, Wei
    Cao, Xiao-Lan
    Xiang, Yu-Tao
    Zink, Mathias
    Kane, John M.
    Nielsen, Jimmi
    Leucht, Stefan
    Correll, Christoph U.
    WORLD PSYCHIATRY, 2017, 16 (01) : 77 - 89
  • [32] Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinoma
    Parikh, Neehar D.
    Marshall, Alexander
    Betts, Keith A.
    Song, Jinlin
    Zhao, Jing
    Yuan, Muhan
    Wu, Aozhou
    Huff, Keith D.
    Kim, Richard
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (05) : 343 - 352
  • [33] SYSTEMATIC REVIEW AND META-ANALYSIS ON THE EFFICACY OF LEFLUNOMIDE VS. METHOTREXATE AS MONOTHERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA)
    Espinosa, F.
    Arce-Salinas, C. A.
    Alfaro-Lara, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 739 - 740
  • [34] Nivolumab plus Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis
    Ando, Koichi
    Kishino, Yasunari
    Homma, Tetsuya
    Kusumoto, Sojiro
    Yamaoka, Toshimitsu
    Tanaka, Akihiko
    Ohmori, Tohru
    Ohnishi, Tsukasa
    Sagara, Hironori
    CANCERS, 2020, 12 (07) : 1 - 19
  • [35] GASTROINTESTINAL ADVERSE EVENTS IN LUNG CANCER PATIENTS TREATED WITH IPILIMUMAB AND NIVOLUMAB USING REAL-WORLD DATA
    Zhao, Y.
    Bian, J.
    Guo, Y.
    VALUE IN HEALTH, 2022, 25 (07) : S591 - S591
  • [36] Cardiovascular events in patients treated with bempedoic acid vs. placebo: systematic review and meta-analysis
    Mutschlechner, D.
    Tscharre, M.
    Huber, K.
    Gremmel, T.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [37] Cardiovascular events in patients treated with bempedoic acid vs. placebo: systematic review and meta-analysis
    Mutschlechner, D.
    Tscharre, M.
    Huber, K.
    Gremmel, T.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [38] Intravenous colistin combination antimicrobial treatment vs. monotherapy: a systematic review and meta-analysis
    Vardakas, Konstantinos Z.
    Mavroudis, Andreas D.
    Georgiou, Maria
    Falagas, Matthew E.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2018, 51 (04) : 535 - 547
  • [39] Relation of overall tumor burden with severe immune-related adverse events in nivolumab plus ipilimumab treatment for lung cancer
    Toshiyuki Sumi
    Motoki Sekikawa
    Yuta Nagahisa
    Keigo Matsuura
    Naoki Shijubou
    Koki Kamada
    Hiroki Watanabe
    Yuichi Yamada
    Yusuke Tanaka
    Hirofumi Chiba
    Investigational New Drugs, 2022, 40 : 1315 - 1321
  • [40] Relation of overall tumor burden with severe immune-related adverse events in nivolumab plus ipilimumab treatment for lung cancer
    Sumi, Toshiyuki
    Sekikawa, Motoki
    Nagahisa, Yuta
    Matsuura, Keigo
    Shijubou, Naoki
    Kamada, Koki
    Watanabe, Hiroki
    Yamada, Yuichi
    Tanaka, Yusuke
    Chiba, Hirofumi
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (06) : 1315 - 1321
12345